Cronos Group Inc (CRON)vsZoetis Inc (ZTS)
CRON
Cronos Group Inc
$3.14
-0.63%
HEALTHCARE · Cap: $1.16B
ZTS
Zoetis Inc
$72.97
+0.15%
HEALTHCARE · Cap: $30.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Zoetis Inc generates 5219% more annual revenue ($9.53B vs $179.09M). CRON leads profitability with a 39.1% profit margin vs 27.7%. ZTS trades at a lower P/E of 12.0x. CRON earns a higher WallStSmart Score of 61/100 (C+).
CRON
Buy61
out of 100
Grade: C+
ZTS
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CRON.
Margin of Safety
+11.3%
Fair Value
$145.00
Current Price
$72.97
$72.03 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 39 of every $100 in revenue as profit
Revenue surging 58.4% year-over-year
Earnings expanding 126.8% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Attractively priced relative to earnings
Every $100 of equity generates 83 in profit
Strong operational efficiency at 40.7%
Safe zone — low bankruptcy risk
Keeps 28 of every $100 in revenue as profit
Areas to Watch
Smaller company, higher risk/reward
ROE of -0.2% — below average capital efficiency
Trading at 9.3x book value
1.2% earnings growth
Expensive relative to growth rate
Revenue declined 0.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : CRON
The strongest argument for CRON centers on Price/Book, Profit Margin, Revenue Growth. Profitability is solid with margins at 39.1% and operating margin at 15.4%. Revenue growth of 58.4% demonstrates continued momentum.
Bull Case : ZTS
The strongest argument for ZTS centers on P/E Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 27.7% and operating margin at 40.7%.
Bear Case : CRON
The primary concerns for CRON are Market Cap, Return on Equity.
Bear Case : ZTS
The primary concerns for ZTS are Price/Book, EPS Growth, PEG Ratio. Debt-to-equity of 2.93 is elevated, increasing financial risk.
Key Dynamics to Monitor
CRON profiles as a growth stock while ZTS is a declining play — different risk/reward profiles.
CRON carries more volatility with a beta of 1.28 — expect wider price swings.
CRON is growing revenue faster at 58.4% — sustainability is the question.
ZTS generates stronger free cash flow (538M), providing more financial flexibility.
Bottom Line
CRON scores higher overall (61/100 vs 58/100), backed by strong 39.1% margins and 58.4% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cronos Group Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Cronos Group Inc. is a cannabinoid company. The company is headquartered in Toronto, Canada.
Visit Website →Zoetis Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?